Your browser doesn't support javascript.
loading
Direct-to-implant breast reconstruction after neoadjuvant chemotherapy: A safe option? / Reconstrucción inmediata mediante implante directo tras quimioterapia neoadyuvante. ¿Es una práctica segura?
Allué Cabañuz, Marta; Arribas Del Amo, Maria Dolores; Gil Romea, Ismael; Val-Carreres Rivera, María Pilar; Sousa Domínguez, Ramón; Güemes Sánchez, Antonio Tomás.
Afiliación
  • Allué Cabañuz M; Unidad de Mama, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España. Electronic address: martitaallue@hotmail.com.
  • Arribas Del Amo MD; Unidad de Mama, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
  • Gil Romea I; Unidad de Mama, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
  • Val-Carreres Rivera MP; Unidad de Mama, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
  • Sousa Domínguez R; Unidad de Mama, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
  • Güemes Sánchez AT; Unidad de Mama, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España; Universidad de Zaragoza, Zaragoza, España.
Cir Esp (Engl Ed) ; 97(10): 575-581, 2019 Dec.
Article en En, Es | MEDLINE | ID: mdl-31530386
INTRODUCTION: Immediate reconstruction (IBR) after mastectomy in patients who have received neoadjuvant chemotherapy (NACT) remains controversial. The aim of this study is to analyze and compare oncological results as well as complication and reoperation rates in patients undergoing NACT and a control group. METHODS: Retrospective observational case-control study of patients with breast cancer who underwent bilateral mastectomy and direct-to-implant IBR (BMIBR) from 2000-2016. The group that received NACT was matched 1:5 to patients without NACT (Control group). We evaluated differences between groups using the χ2 or Fisher test (qualitative variables), Mann-Whitney U or Student's t-test (quantitative variables). The survival analysis was performed using Kaplan-Meier curves and log-rank test (SPSS 22.0). RESULTS: The study included a total of 171 patients with BMIBR: 62 patients (36.3%) after NACT and 109 patients (63.7%) in the control group without NACT. Median follow-up was 52.0 (IQR: 23.0-94.0) months. In both groups, the indication for BMIBR was patient choice (32.7%). There were no statistically significant differences between groups in terms of complication rate (24.2% in the NACT group and 19.3% in the control group [P=.44]), but differences in oncological results were found. Patients in the NACT Group had three times more risk of recurrence at a given time than patients in the control group (3.009 [1.349-6.713]) according to the univariate analysis. CONCLUSIONS: Direct-to-implant IBR after skin-sparing mastectomy is a viable option for breast cancer patients undergoing NACT.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Mamoplastia / Implantes de Mama Tipo de estudio: Observational_studies / Qualitative_research / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En / Es Revista: Cir Esp (Engl Ed) Año: 2019 Tipo del documento: Article Pais de publicación: España
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Mamoplastia / Implantes de Mama Tipo de estudio: Observational_studies / Qualitative_research / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En / Es Revista: Cir Esp (Engl Ed) Año: 2019 Tipo del documento: Article Pais de publicación: España